EUVIMEDDécouvrir EUVIMED
Open access · CC BY 4.0

Combined Effects of Romosozumab and Zoledronate on the Development of Osteonecrosis of the Jaw

Hae-Seo Park iD, Shihyun Kim, Seo-Yeong An, Reuben H Kim iD, Jongho Choi, Moon-Young Kim

Oral Diseases · 2026-09 · 32 (9) · 2815-2825

DOI: 10.1111/odi.70331 ↗

At a glance

Journal article in Oral Diseases, published online on 2026-04-06. Written by Hae-Seo Park and 5 co-authors. Institution: Department of Oral and Maxillofacial Surgery, College of Dentistry, Dankook University, Cheonan, Republic of Korea. Major MEDLINE topics: Zoledronic Acid, Bone Density Conservation Agents, Antibodies, Monoclonal, Bisphosphonate-Associated Osteonecrosis of the Jaw. Cited 2 times so far (Crossref); 39 references. The full text is freely available (open access, CC BY 4.0). Funded by: National Research Foundation of Korea.

RésuméSubjectsRéférences bibliographiquesCiteRelated studies

Abstract (original language)

Objective

This study aimed to assess the occurrence of medication‐related osteonecrosis of the jaw (MRONJ) in mice following the sequential administration of romosozumab and zoledronate and to confirm their inhibitory effects on osteoclast differentiation in vitro. Materials and Methods Thirty‐five female C57BL/6 mice were divided into three groups: romosozumab followed by zoledronate (ROM+ ZOL), saline followed by zoledronate (ZOL), and control (Con) group receiving saline. After drug administration, the maxillary first molars were extracted. Bone healing and necrosis were evaluated using micro‐computed tomography, histomorphometry, and immunohistochemistry. To investigate the mechanism underlying the in vivo study results, the effects of romosozumab and zoledronate were evaluated by analysing tartrate‐resistant acid phosphatase staining and actin ring formation after differentiation of RAW 264.7 cells.

Results

The ROM+ZOL group exhibited more severe bone necrosis than the ZOL and Con groups. The ROM+ZOL group demonstrated a lower bone volume fraction and a reduction in the number of sclerostin‐positive cells, suggesting enhanced osteonecrosis when romosozumab was administered before zoledronate. Moreover, both zoledronate and romosozumab effectively suppressed osteoclast differentiation and function in vitro.

Conclusions

Sequential administration of romosozumab followed by zoledronate may exacerbate the risk of MRONJ, underscoring the need for careful consideration in clinical applications.

Subjects

MeSH terms (MEDLINE)

Zoledronic AcidBone Density Conservation AgentsAntibodies, MonoclonalBisphosphonate-Associated Osteonecrosis of the JawAnimalsFemaleMiceOsteoclastsMice, Inbred C57BLX-Ray MicrotomographyCell DifferentiationRAW 264.7 CellsDrug Therapy, Combination

Author keywords

MRONJhealingosteoclastromosozumabzoledronate

Substances

Zoledronic AcidBone Density Conservation AgentsAntibodies, Monoclonalromosozumab

Authors and institutions

  • Department of Oral and Maxillofacial Surgery, College of Dentistry, Dankook University, Cheonan, Republic of Korea.
  • Department of Oral Pathology, College of Dentistry, Gangneung-Wonju National University, Gangneung-si, Republic of Korea.
  • The Shapiro Family Laboratory of Viral Oncology and Aging Research, Los Angeles, California, USA.
  • UCLA Jonsson Comprehensive Cancer Centre, Los Angeles, California, USA.

ORCID profiles: Hae-Seo Park, Reuben H Kim

Funding

  • National Research Foundation of Korea

Cite

APA

Park, H. S., Kim, S., An, S. Y., Kim, R. H., Choi, J., & Kim, M. Y. (2026). Combined Effects of Romosozumab and Zoledronate on the Development of Osteonecrosis of the Jaw. Oral Diseases, 32(9), 2815-2825. https://doi.org/10.1111/odi.70331

Vancouver

Park HS, Kim S, An SY, Kim RH, Choi J, Kim MY. Combined Effects of Romosozumab and Zoledronate on the Development of Osteonecrosis of the Jaw. Oral Diseases. 2026;32(9):2815-2825. doi:10.1111/odi.70331

BibTeX
@article{Park2026,
  author = {Park, Hae-Seo and Kim, Shihyun and An, Seo-Yeong and Kim, Reuben H and Choi, Jongho and Kim, Moon-Young},
  title = {Combined Effects of Romosozumab and Zoledronate on the Development of Osteonecrosis of the Jaw},
  journal = {Oral Diseases},
  year = {2026},
  volume = {32},
  number = {9},
  pages = {2815--2825},
  doi = {10.1111/odi.70331}
}
Start for free →